Maximum Dose of Entresto Per Administration
The maximum dose of Entresto per administration is 97 mg sacubitril/103 mg valsartan taken twice daily, which represents the target dose for adults with heart failure with reduced ejection fraction (HFrEF). 1
Dosing Details
Standard Adult Dosing
- Target/Maximum dose: 97 mg sacubitril/103 mg valsartan twice daily
- Starting dose: 49 mg sacubitril/51 mg valsartan twice daily (or 24 mg/26 mg twice daily in certain circumstances)
- Titration: Double the dose every 2-4 weeks as tolerated to reach the target dose 1
Special Populations Requiring Dose Adjustment
Patients requiring half the starting dose (24 mg/26 mg twice daily initially):
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)
- Moderate hepatic impairment (Child-Pugh B)
- These patients can still be titrated toward the maximum dose of 97/103 mg twice daily as tolerated 2
Contraindicated populations:
- Severe hepatic impairment (Child-Pugh C) - no studies conducted, not recommended 2
Clinical Context and Evidence
Importance of Target Dose Achievement
The 2022 AHA/ACC/HFSA guidelines emphasize that titration to target doses shown efficacious in randomized controlled trials is recommended (Class 1, Level A evidence) to reduce cardiovascular mortality and heart failure hospitalizations 1. However, real-world data shows achieving target doses can be challenging:
- In clinical practice, only 27% of patients achieved the 200 mg (97/103 mg) twice daily dose within 6 months 3
- Main barriers include hypotension (25%), slower uptitration protocols (55%), and patient noncompliance 3
Dose-Response Relationship
Research demonstrates clear dose-dependent benefits:
- Mortality and hospitalization: The 97/103 mg dose showed significantly lower all-cause mortality (9.27%) compared to 49/51 mg (17.58%) and 24/26 mg (29.63%) doses 4
- Heart failure hospitalization: Rates were 16.10% with 97/103 mg versus 29.14% with 24/26 mg (HR 1.79,95% CI 1.18-2.73) 4
- NT-proBNP reduction: Benefits were consistent across all dose levels, though higher doses trended toward greater reductions 5
Key Clinical Pitfalls
Common dosing errors to avoid:
- Premature dose acceptance: Don't settle for lower doses without attempting uptitration; the mortality benefit is dose-dependent 4
- Excessive caution with blood pressure: Symptomatic hypotension occurred in only 1.35-fold higher rates versus control, and efficacy was maintained across dose levels 6
- Overlooking titration windows: Guidelines suggest titration as frequently as every 1-2 weeks is reasonable, not the slower protocols often used in practice 1
Safety considerations at maximum dose:
- Hypotension is the most likely adverse effect from overdosage 2
- In healthy volunteers, doses up to 583 mg sacubitril/617 mg valsartan (single dose) and 437 mg/463 mg (14 days) were well tolerated 2
- The drug is unlikely to be removed by hemodialysis due to high protein binding 2
Practical Uptitration Algorithm
- Start: 49/51 mg twice daily (or 24/26 mg if severe renal/moderate hepatic impairment)
- Week 2-4: Double to 97/103 mg twice daily if SBP >100 mmHg and no symptomatic hypotension
- Monitor: Blood pressure, renal function, potassium (especially if on MRA - 10% hyperkalemia risk) 7
- Maintain: 97/103 mg twice daily as the therapeutic target dose
The evidence strongly supports aggressive uptitration to the maximum dose of 97/103 mg twice daily whenever tolerated, as this provides the greatest mortality and morbidity benefit in HFrEF patients 1, 4.